医学
类风湿性关节炎
骨重建
骨吸收
肾移植
骨矿物
吸收
移植
骨质疏松症
肾
内科学
钙化
泌尿科
作者
Li Yan Sun,Jun Tao,Zhijian Han,Hao Chen,Zhengkai Huang,Zijie Wang,Shuang Fei,Chuanjian Suo,Xiaobing Ju,Ruoyun Tan,Min Gu
出处
期刊:Renal Failure
[Taylor & Francis]
日期:2023-10-31
卷期号:45 (2): 2256418-2256418
被引量:4
标识
DOI:10.1080/0886022x.2023.2256418
摘要
BACKGROUND: Iguratimod has been shown to promote bone formation and inhibit bone resorption in rheumatoid arthritis patients. We aimed to explore its effect on bone metabolism and vascular calcification (VC) in kidney transplant recipients (KTRs). METHODS: analysis was conducted among the subjects in our previous randomized clinical trial (NCT02839941). Forty-three KTRs completing bone metabolism 52 weeks after enrollment were selected for this analysis, among whom 27 patients received VC examinations. In the iguratimod group, iguratimod (25 mg twice daily) was added adjuvant to the traditional triple regimen. At the 52-week follow-up, the following parameters were assessed: serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone (iPTH), bone alkaline phosphatase (BALP), osteocalcin, type I collagen N-terminal peptide (NTx), type I collagen C-terminal peptide (CTx), bone mineral density (BMD) of the femoral neck and lumbar spine, coronary artery calcification (CAC) and thoracic aortic calcification (TAC). Bone metabolic and VC indices were compared between the two groups using the independent samples t test and Wilcoxon nonparametric test. RESULTS: = 0.036) than the control group. There was no significant difference in serum calcium, phosphorus, 25-hydroxyvitamin D, iPTH and BMD between the groups. Iguratimod could reduce bone turnover markers (BTMs) at both high and low iPTH levels. The adverse effect of iguratimod was mild and tolerable. CONCLUSION: Iguratimod is safe, can reduce BTMs and may could attenuate VC in the first year after KT.
科研通智能强力驱动
Strongly Powered by AbleSci AI